TLR4-mediated immunomodulatory properties of the bacterial metalloprotease arazyme in preclinical tumor models

References

• Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol Rev 2011; 239:27-44; PMID:21198663; http://dx.doi.org/10.1111/j.1600-065X.2010.00979.x
   PubMed Web of Science ®Google Scholar
• Zigler M, Shir A, Levitzki A. Targeted cancer immunotherapy. Curr Opin Pharmacol 2013; 13:504-10; PMID:23648271; http://dx.doi.org/10.1016/j.coph.2013.04.003
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 2010; 28 Suppl 3:C25-36; PMID:20713254; http://dx.doi.org/10.1016/j.vaccine.2010.07.021
   PubMedGoogle Scholar
• de Melo FM, Braga CJ, Pereira FV, Maricato JT, Origassa CS, Souza MF, Amanda C Melo1, Silva P, Tomaz SL, Gimenes KP et al. Anti-metastatic immunotherapy based on mucosal administration of flagellin and immunomodulatory P10. Immunol Cell Biol 2015; 93:86-98; PMID:25223833; http://dx.doi.org/10.1038/icb.2014.74
   PubMed Web of Science ®Google Scholar
• Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 2008; 65:3231-40; PMID:18668203; http://dx.doi.org/10.1007/s00018-008-8228-6
   PubMed Web of Science ®Google Scholar
• Bogunovic D, Manches O, Godefroy E, Yewdall A, Gallois A, Salazar AM, Marie I, Levy DE, Bhardwaj N. TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity. Cancer Res 2011; 71:5467-76; PMID:21730023; http://dx.doi.org/10.1158/0008-5472.CAN-10-3988
   PubMed Web of Science ®Google Scholar
• Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, Cruz CM, Angiulli A, Angiulli F, Ritter E et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 2008; 181:776-84; PMID:18566444; http://dx.doi.org/10.4049/jimmunol.181.1.776
   PubMed Web of Science ®Google Scholar
• Wilensky A, Tzach-Nahman R, Potempa J, Shapira L, Nussbaum G. Porphyromonas gingivalis gingipains selectively reduce CD14 expression, leading to macrophage hyporesponsiveness to bacterial infection. J Innate Immun 2015; 7:127-35; PMID:25228314; http://dx.doi.org/10.1159/000365970
   PubMed Web of Science ®Google Scholar
• Palm E, Khalaf H, Bengtsson T. Suppression of inflammatory responses of human gingival fibroblasts by gingipains from Porphyromonas gingivalis. Mol Oral Microbiol 2015; 30:74-85; PMID:25055828; http://dx.doi.org/10.1111/omi.12073
   PubMed Web of Science ®Google Scholar
• Klarstrom Engstrom K, Khalaf H, Kalvegren H, Bengtsson T. The role of Porphyromonas gingivalis gingipains in platelet activation and innate immune modulation. Mol Oral Microbiol 2015; 30:62-73; PMID:25043711; http://dx.doi.org/10.1111/omi.12067
   PubMed Web of Science ®Google Scholar
• Beuth J. Proteolytic enzyme therapy in evidence-based complementary oncology: fact or fiction? Integr Cancer Ther 2008; 7:311-6; PMID:19116226; http://dx.doi.org/10.1177/1534735408327251
   PubMed Web of Science ®Google Scholar
• Guimaraes-Ferreira CA, Rodrigues EG, Mortara RA, Cabral H, Serrano FA, Ribeiro-dos-Santos R, Travassos LR. Antitumor effects in vitro and in vivo and mechanisms of protection against melanoma B16F10-Nex2 cells by fastuosain, a cysteine proteinase from Bromelia fastuosa. Neoplasia 2007; 9:723-33; PMID:17898868; http://dx.doi.org/10.1593/neo.07427
   PubMed Web of Science ®Google Scholar
• Bersanetti PA, Park H-Y, Bae KS, Son K-H, Shin D-H, Hirata IY, Juliano MA, Carmona AK, Juliano L. Characterization of arazyme, an exocellular metalloprotease isolated from Serratia proteamaculans culture medium. Enzyme and Microbial Technology 2005; 37:574-81; http://dx.doi.org/10.1016/j.enzmictec.2005.01.041
   Web of Science ®Google Scholar
• Pereira FV, Ferreira-Guimaraes CA, Paschoalin T, Scutti JA, Melo FM, Silva LS, Tiago M, Matsuo AL, Juliano L, Juliano MA et al. A natural bacterial-derived product, the metalloprotease arazyme, inhibits metastatic murine melanoma by inducing MMP-8 cross-reactive antibodies. PLoS One 2014; 9:e96141; PMID:24788523; http://dx.doi.org/10.1371/journal.pone.0096141
   PubMedGoogle Scholar
• Dobroff AS, Rodrigues EG, Moraes JZ, Travassos LR. Protective, anti-tumor monoclonal antibody recognizes a conformational epitope similar to melibiose at the surface of invasive murine melanoma cells. Hybrid Hybridomics 2002; 21:321-31; PMID:12470474; http://dx.doi.org/10.1089/153685902761022661
   PubMedGoogle Scholar
• Sancho D, Joffre OP, Keller AM, Rogers NC, Martinez D, Hernanz-Falcon P, Rosewell I, Reis e Sousa C. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 2009; 458:899-903; PMID:19219027; http://dx.doi.org/10.1038/nature07750
   PubMed Web of Science ®Google Scholar
• Dias BR, Rodrigues EG, Nimrichter L, Nakayasu ES, Almeida IC, Travassos LR. Identification of iGb3 and iGb4 in melanoma B16F10-Nex2 cells and the iNKT cell-mediated antitumor effect of dendritic cells primed with iGb3. Mol Cancer 2009; 8:116; PMID:19968878; http://dx.doi.org/10.1186/1476-4598-8-116
   PubMed Web of Science ®Google Scholar
• Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, Kotb M, Gillies SD, King M, Mangada J et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005; 174:6477-89; PMID:15879151; http://dx.doi.org/10.4049/jimmunol.174.10.6477
   PubMed Web of Science ®Google Scholar
• Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol 2007; 7:118-30; PMID:17259968; http://dx.doi.org/10.1038/nri2017
   PubMed Web of Science ®Google Scholar
• Zaidi MR, Merlino G. The two faces of interferon-gamma in cancer. Clin Cancer Res 2011; 17:6118-24; PMID:21705455; http://dx.doi.org/10.1158/1078-0432.CCR-11-0482
   PubMed Web of Science ®Google Scholar
• Liao YP, Schaue D, McBride WH. Modification of the tumor microenvironment to enhance immunity. Front Biosci 2007; 12:3576-600; PMID:17485323; http://dx.doi.org/10.2741/2336
   PubMed Web of Science ®Google Scholar
• Marchi LH, Paschoalin T, Travassos LR, Rodrigues EG. Gene therapy with interleukin-10 receptor and interleukin-12 induces a protective interferon-gamma-dependent response against B16F10-Nex2 melanoma. Cancer Gene Ther 2011; 18:110-22; PMID:20885448; http://dx.doi.org/10.1038/cgt.2010.58
   PubMed Web of Science ®Google Scholar
• Hiniker SM, Chen DS, Reddy S, Chang DT, Jones JC, Mollick JA, Swetter SM, Knox SJ. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol 2012; 5:404-7; PMID:23323154; http://dx.doi.org/10.1593/tlo.12280
   PubMed Web of Science ®Google Scholar
• Pufnock JS, Cigal M, Rolczynski LS, Andersen-Nissen E, Wolfl M, McElrath MJ, Greenberg PD. Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28. Blood 2011; 117:6542-51; PMID:21493800; http://dx.doi.org/10.1182/blood-2010-11-317966
   PubMed Web of Science ®Google Scholar
• Andersen BM, Ohlfest JR. Increasing the efficacy of tumor cell vaccines by enhancing cross priming. Cancer Lett 2012; 325:155-64; PMID:22809568; http://dx.doi.org/10.1016/j.canlet.2012.07.012
   PubMed Web of Science ®Google Scholar
• Osorio F, Reis e Sousa C. Myeloid C-type lectin receptors in pathogen recognition and host defense. Immunity 2011; 34:651-64; PMID:21616435; http://dx.doi.org/10.1016/j.immuni.2011.05.001
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499-511; PMID:15229469; http://dx.doi.org/10.1038/nri1391
   PubMed Web of Science ®Google Scholar
• Mourao-Sa D, Robinson MJ, Zelenay S, Sancho D, Chakravarty P, Larsen R, Plantinga M, Van Rooijen N, Soares MP, Lambrecht B et al. CLEC-2 signaling via Syk in myeloid cells can regulate inflammatory responses. Eur J Immunol 2011; 41:3040-53; PMID:21728173; http://dx.doi.org/10.1002/eji.201141641
   PubMed Web of Science ®Google Scholar
• Pagano RL, Sampaio SC, Juliano MA, Juliano L, Giorgi R. Involvement of proteinase-activated receptors 1 and 2 in spreading and phagocytosis by murine adherent peritoneal cells: modulation by the C-terminal of S100A9 protein. Eur J Pharmacol 2010; 628:240-6; PMID:19941849; http://dx.doi.org/10.1016/j.ejphar.2009.11.033
   PubMed Web of Science ®Google Scholar
• Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev Immunol 2002; 20:55-72; PMID:11861597; http://dx.doi.org/10.1146/annurev.immunol.20.091301.131133
   PubMed Web of Science ®Google Scholar
• Korhonen R, Huotari N, Hommo T, Leppanen T, Moilanen E. The expression of interleukin-12 is increased by MAP kinase phosphatase-1 through a mechanism related to interferon regulatory factor 1. Mol Immunol 2012; 51:219-26; PMID:22464096; http://dx.doi.org/10.1016/j.molimm.2012.03.019
   PubMed Web of Science ®Google Scholar
• Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994; 64:529-64; PMID:7724661; http://dx.doi.org/10.1016/0163-7258(94)90023-X
   PubMed Web of Science ®Google Scholar
• Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol 2008; 179:53-6; PMID:17997439; http://dx.doi.org/10.1016/j.juro.2007.08.122
   PubMed Web of Science ®Google Scholar
• Bernardes N, Seruca R, Chakrabarty AM, Fialho AM. Microbial-based therapy of cancer: current progress and future prospects. Bioeng Bugs 2010; 1:178-90; PMID:21326924; http://dx.doi.org/10.4161/bbug.1.3.10903
   PubMedGoogle Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258
   PubMed Web of Science ®Google Scholar
• Rodrigues EG, Garofalo AS, Travassos LR. Endogenous accumulation of IFN-gamma in IFN-gamma-R(−/−) mice increases resistance to B16F10-Nex2 murine melanoma: a model for direct IFN-gamma anti-tumor cytotoxicity in vitro and in vivo. Cytokines Cell Mol Ther 2002; 7:107-16; PMID:12850810; http://dx.doi.org/10.1080/13684730310000121
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21:137-48; PMID:15308095; http://dx.doi.org/10.1016/j.immuni.2004.07.017
   PubMed Web of Science ®Google Scholar
• Wu R, Forget MA, Chacon J, Bernatchez C, Haymaker C, Chen JQ, Hwu P, Radvanyi LG. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 2012; 18:160-75; PMID:22453018; http://dx.doi.org/10.1097/PPO.0b013e31824d4465
   PubMed Web of Science ®Google Scholar
• Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, Omholt H, Munthe LA, Dembic Z, Corthay A et al. How do CD4(+) T cells detect and eliminate tumor cells that either lack or express MHC class II molecules? Front Immunol 2014; 5:174; PMID:24782871; http://dx.doi.org/10.3389/fimmu.2014.00174
   PubMed Web of Science ®Google Scholar
• Steer HJ, Lake RA, Nowak AK, Robinson BW. Harnessing the immune response to treat cancer. Oncogene 2010; 29:6301-13; PMID:20856204; http://dx.doi.org/10.1038/onc.2010.437
   PubMed Web of Science ®Google Scholar
• Yong X, Xiao YF, Luo G, He B, Lu MH, Hu CJ, Guo H, Yang SM. Strategies for enhancing vaccine-induced CTL antitumor immune responses. J Biomed Biotechnol 2012; 2012:605045; PMID:23093850; http://dx.doi.org/10.1155/2012/605045
   PubMed Web of Science ®Google Scholar
• Piras V, Selvarajoo K. Beyond MyD88 and TRIF pathways in toll-like receptor signaling. Front Immunol 2014; 5:70; PMID:24605113; http://dx.doi.org/10.3389/fimmu.2014.00070
   PubMed Web of Science ®Google Scholar
• Gandhapudi SK, Chilton PM, Mitchell TC. TRIF is required for TLR4 mediated adjuvant effects on T cell clonal expansion. PLoS One 2013; 8:e56855; PMID:23457630; http://dx.doi.org/10.1371/journal.pone.0056855
   PubMedGoogle Scholar
• Dadaglio G, Fayolle C, Zhang X, Ryffel B, Oberkampf M, Felix T, Hervas-Stubbs S, Osicka R, Sebo P, Ladant D et al. Antigen targeting to CD11b+ dendritic cells in association with TLR4/TRIF signaling promotes strong CD8+ T cell responses. J Immunol 2014; 193:1787-98; PMID:25024388; http://dx.doi.org/10.4049/jimmunol.1302974
   PubMed Web of Science ®Google Scholar
• Wei F, Yang D, Tewary P, Li Y, Li S, Chen X, Howard OM, Bustin M, Oppenheim JJ. The alarmin HMGN1 contributes to antitumor immunity and is a potent immunoadjuvant. Cancer Res 2014; 74:5989-98; PMID:25205103; http://dx.doi.org/10.1158/0008-5472.CAN-13-2042
   PubMed Web of Science ®Google Scholar
• Fang H, Ang B, Xu X, Huang X, Wu Y, Sun Y, Wang W, Li N, Cao X, Wan T. TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells. Cell Mol Immunol 2014; 11:150-9; PMID:24362470; http://dx.doi.org/10.1038/cmi.2013.59
   PubMed Web of Science ®Google Scholar
• Saenz R, Futalan D, Leutenez L, Eekhout F, Fecteau JF, Sundelius S, Sundqvist S, Larsson M, Hayashi T, Minev B et al. TLR4-dependent activation of dendritic cells by an HMGB1-derived peptide adjuvant. J Transl Med 2014; 12:211; PMID:25123824; http://dx.doi.org/10.1186/1479-5876-12-211
   PubMed Web of Science ®Google Scholar
• Chaganty BK, Murthy AK, Evani SJ, Li W, Guentzel MN, Chambers JP, Zhong G, Arulanandam BP. Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge. Vaccine 2010; 28:2323-9; PMID:20056182; http://dx.doi.org/10.1016/j.vaccine.2009.12.064
   PubMed Web of Science ®Google Scholar
• Bonifait L, Grenier D. The SspA subtilisin-like protease of Streptococcus suis triggers a pro-inflammatory response in macrophages through a non-proteolytic mechanism. BMC Microbiol 2011; 11:47; PMID:21362190; http://dx.doi.org/10.1186/1471-2180-11-47
   PubMed Web of Science ®Google Scholar
• Li X1, Syrovets T, Paskas S, Laumonnier Y, Simmet T. Mature dendritic cells express functional thrombin receptors triggering chemotaxis and CCL18/pulmonary and activation-regulated chemokine induction. J Immunol 2008; 181:1215-23; PMID:18606675; http://dx.doi.org/10.4049/jimmunol.181.2.1215
   PubMed Web of Science ®Google Scholar
• Ramelli G1, Fuertes S, Narayan S, Busso N, Acha-Orbea H, So A. Protease-activated receptor 2 signalling promotes dendritic cell antigen transport and T-cell activation in vivo. Immunology 2010; 129:20-7; PMID:19845798; http://dx.doi.org/10.1111/j.1365-2567.2009.03144.x
   PubMed Web of Science ®Google Scholar
• Fields RC1, Schoenecker JG, Hart JP, Hoffman MR, Pizzo SV, Lawson JH. Protease-activated receptor-2 signaling triggers dendritic cell development. Am J Pathol 2003; 162:1817-22; PMID:12759239; http://dx.doi.org/10.1016/S0002-9440(10)64316-7
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 2014; 27:1-7; PMID:24413387; http://dx.doi.org/10.1016/j.coi.2013.12.005
   PubMed Web of Science ®Google Scholar